Ron Alfa is Vice President, Discovery and Product at Recursion Pharmaceuticals where he manages scientific product development and external alliances across Recursion’s AI-enabled discovery platform. Ron Alfa’s scientific contributions prior to Recursion span Neurosciences, Metabolism, and Genetics.
Date | Company Name | Round | Money Raised | Industry | |
---|---|---|---|---|---|
Dec 6, 2022 | Infinimmune | Seed | $12M | Biotechnology | Detail |